Drug Trial Radar · NCT06393374
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,530
Planned (sponsor's estimate)
Start
Jun 24, 2024
Primary completion
Dec 16, 2030
Study completion Dec 14, 2037
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sacituzumab tirumotecan plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Conditions
- Triple-Negative Breast Cancer
Interventions
PembrolizumabBiological
Pembrolizumab 400 mg intravenous (IV) infusion q6w
Sacituzumab tirumotecanBiological
Sacituzumab tirumotecan 4 mg/kg IV infusion q2w
CapecitabineDrug
Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-Free Survival (iDFS)Time frame: Up to approximately 77 months
Locations
317 sites in 31 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care ( Site 0001)
Mobile, Alabama · Recruiting
Ironwood Cancer & Research Centers-Research ( Site 0054)
Chandler, Arizona · Recruiting
MemorialCare Orange Coast Medical Center ( Site 9501)
Fountain Valley, California · Recruiting
Scripps Cancer Center ( Site 0052)
La Jolla, California · Recruiting
Cancer and Blood Specialty Clinic ( Site 0008)
Los Alamitos, California · Completed
Kaiser Permanente - Oakland ( Site 0079)
Oakland, California · Recruiting
Profound Research LLC ( Site 0105)
Oceanside, California · Completed
Kaiser Permanente - Roseville ( Site 0081)
Roseville, California · Recruiting
Kaiser Permanente - San Francisco ( Site 0080)
San Francisco, California · Recruiting
Kaiser Permanente - Santa Clara ( Site 0082)
Santa Clara, California · Recruiting
Providence Medical Foundation ( Site 9543)
Santa Rosa, California · Recruiting
Kaiser Permanente Vallejo Medical Center ( Site 0060)
Vallejo, California · Recruiting
Kaiser Permanente - Walnut Creek ( Site 0078)
Walnut Creek, California · Recruiting
Bass Medical Group ( Site 0089)
Walnut Creek, California · Completed
Cancer Centers of Colorado St. Mary's Regional Hospital ( Site 0046)
Grand Junction, Colorado · Recruiting
University of Connecticut Health Center ( Site 0128)
Farmington, Connecticut · Recruiting
Yale Cancer Center ( Site 0053)
New Haven, Connecticut · Recruiting
Helen F. Graham Cancer Center & Research Institute ( Site 0018)
Newark, Delaware · Recruiting
AdventHealth Altamonte Springs ( Site 0125)
Altamonte Springs, Florida · Recruiting
Orlando Health Cancer Institute ( Site 0030)
Orlando, Florida · Recruiting
Comprehensive Hematology Oncology ( Site 0091)
St. Petersburg, Florida · Completed
Cleveland Clinic Martin North Hospital ( Site 0114)
Stuart, Florida · Recruiting
Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0040)
Thomasville, Georgia · Completed
Illinois Cancer Specialists (ICS) ( Site 8010)
Arlington Heights, Illinois · Recruiting
Southern Illinois Hospital Services ( Site 9547)
Carterville, Illinois · Recruiting
Orchard Healthcare Research Inc. ( Site 0014)
Skokie, Illinois · Recruiting
Northwest Cancer Center - Dyer Clinic ( Site 0097)
Dyer, Indiana · Recruiting
Parkview Research Center at Parkview Regional Medical Center ( Site 0011)
Fort Wayne, Indiana · Recruiting
Cancer Center of Kansas ( Site 0004)
Wichita, Kansas · Completed
Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0044)
Edgewood, Kentucky · Recruiting
CHRISTUS St. Frances Cabrini Hospital Center for Cancer Care ( Site 0109)
Alexandria, Louisiana · Recruiting
Ochsner LSU Health - Monroe Medical Center, Family Medicine Clinic ( Site 0063)
Monroe, Louisiana · Completed
Louisiana State University Health Sciences Shreveport ( Site 0029)
Shreveport, Louisiana · Recruiting
Holy Cross Hospital ( Site 0069)
Silver Spring, Maryland · Recruiting
University of Michigan ( Site 0103)
Ann Arbor, Michigan · Recruiting
Henry Ford Health ( Site 0010)
Detroit, Michigan · Recruiting
Profound Research LLC ( Site 0074)
Royal Oak, Michigan · Completed
Metro-Minnesota Community Clinical Oncology ( Site 0031)
Saint Louis Park, Minnesota · Recruiting
University of Mississippi Medical Center ( Site 0043)
Jackson, Mississippi · Recruiting
SSM Health Cancer Care - Fenton ( Site 0088)
Fenton, Missouri · Completed
Showing 40 of 317 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.